News & Announcements

AMP RA Lupus Year 6

The Accelerating Medicines Partnership (AMP) is extending the Rhemautoid Arthritis (RA), Systemic Lupus Erythematosus (SLE) & Related Autoimmune Disorders program to a sixth year to further analyze the existing dataset.

Kidney injury detection

FNIH Biomarkers Consortium and Critical Path Institute achieve the first ever qualification of a clinical safety biomarker by the U.S. Food and Drug Administration.

Dr. Michael Fox

Michael Fox, M.D., Ph.D., developed innovative techniques to map brain connectivity that can be translated into new treatments for neurological diseases.


Dr. Maria Freire

Learn more about Dr. Freire in this “Women in Business” Q&A featured in the Huffington Post.

Stevie Award

Learn how the AMP RA/Lupus project is helping patients with rheumatoid arthritis and lupus.

 FNIH Rated #1 Charity

The FNIH is delighted to once again earn the highest, 4-star rating from Charity Navigator.


Front Page: